EAACI Biologicals Guidelines – Recommendations for severe asthma

Ioana Agache, Cezmi Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Derek K. Chu, Stefano Del Giacco, Thomas Eiwegger, Breda Flood, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Irene Hernández‐martín, Rebeca Knibb, Mika Mäkelä, Parameswaran Nair, Liam O13037mahonyNikolaos G. Papadopoulos, Alberto Papi, Hae‐sim Park, Luis Pérez De Llano, Oliver Pfaar, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Oscar Palomares, Marek Jutel

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, comorbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based) and its cost‐effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
Original languageEnglish
Early online date2 Jun 2020
Publication statusE-pub ahead of print - 2 Jun 2020


Dive into the research topics of 'EAACI Biologicals Guidelines – Recommendations for severe asthma'. Together they form a unique fingerprint.

Cite this